Hims & Hers cuts 2026 earnings outlook despite 49% revenue growth
Hims & Hers Health (HIMS) reported 49% revenue growth in Q3, but lowered its 2026 adjusted EBITDA forecast to $257M-$277M. Revenue guidance was tightened to $3.13B-$3.15B, with Q4 sales expected at $875M-$895M. International revenue surged 321%, while gross margin contracted to 57% from 74%. The company reported a net loss of $33M, with adjusted EBITDA margin falling to 9% from 13%.
How this was made
The 30-second read
Why it matters
The guidance cut suggests earnings will fall short of prior expectations, likely prompting a share price decline.
Market read
The new guidance is a material update for investors and may trigger re‑rating of the stock.
What to watch
AI‑led customer experience rollout could improve future profitability if executed well.
Background
Hims & Hers reported a 49% revenue jump in Q3 but lowered its full‑year outlook, highlighting margin compression.
Ticker impact
Hims & Hers cut its 2026 adjusted EBITDA and revenue guidance despite strong Q3 revenue growth.
likely downward pressure as investors price in lower earnings expectations
The company narrowed its EBITDA range and tightened revenue guidance, which typically leads to a sell‑off.
Market effects
Telehealth sector may face broader scrutiny on margin sustainability.
U.S. healthcare stocks could see modest pullback.
Limited; impact confined to U.S. listed telehealth players.
Counterpoint
If international expansion continues, margin pressure may be temporary, offering a buying opportunity on dip.
Key entities
- companyHims & Hers Health
U.S. telehealth provider (NYSE:HIMS).
